

1FW 2853

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 16, 2007 Signature: David A. Gass
(David A. Gass)

Docket No.: 28113/39467A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/567,630

Confirmation No.: 2853

Filed: May 30, 2006

Art Unit: 1655

For: MATERIALS AND METHODS FOR
COLORECTAL CANCER SCREENING,
DIAGNOSIS, AND THERAPY

Examiner: Not Yet Assigned

SECOND INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the Applicants request that the Patent and Trademark Office consider the references listed on the attached PTO/SB/08 during the prosecution of this application, and make them of record therein, to appear among the "References Cited" on any issued patent..

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an

admission that any patent, publication or other information referred to therein is "prior art" for this invention..

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28113/39467A.

Dated: February 16, 2007

Respectfully submitted,

By 

David A. Gass

Registration No.: 38,153

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/567,630-Conf. #2853
				Filing Date	May 30, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	1655
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	28113/39467A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A7	US-5,750,652	05-12-1998	Artavanis-Tsakonas et al.	
	A8	US-5,780,300	07-14-1998	Artavanis-Tsakonas et al.	
	A9	US-6,004,924	12-21-1999	Ish-Horowicz et al.	
	A10	US-6,083,904	07-04-2000	Artavanis-Tsakonas	
	A11	US-6,121,045	09-19-2000	McCarthy et al.	
	A12	US-6,262,025	07-17-2001	Ish-Horowicz et al.	
	A13	US-6,291,210	09-18-2001	Sakano et al.	
	A14	US-6,380,362	04-30-2002	Watson et al.	
	A15	US-6,433,138	08-13-2002	Zimrin et al.	
	A16	US-6,436,650	08-20-2002	Artavanis-Tsakonas et al.	
	A17	US-2003/0087807-A1	05-08-2003	Greenspan	
	A18	US-2003/0224516	12-04-2003	Dobie	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B7	WO-00/06726	02-10-2000	Amgen, Inc.		
	B8	WO-01/12664	02-22-2001	Chiron Corporation		
	B9	WO-02/24221	03-28-2000	Genetech, Inc.		
	B10	WO-03/027285	04-03-2003	Bionomics Ltd.		
	B11	WO-03/047532	06-12-2003	Baylor College of Medicine		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C59	Kinzler et al., "Lessons from Hereditary Colorectal Cancer," <i>Cell</i> , 87, 159-170 (1996).	
	C60	Lohela et al., "Lymphangiogenic Growth Factors, Receptors and Therapies," <i>Thrombosis and Haemostasis</i> , 90(2):167-184 (2003).	
	C61	Maillard et al., "Notch and Cancer: Best to Avoid the Ups and Downs," <i>Cancer Cell</i> , 203-205 (2003).	
	C62	Petrova et al., "Effects of Lymphatic Transcription Factor Prox-1 on Cell Cycle Progression," <i>J. Submicro. Cyt. Path.</i> , 32(3):406 (2000).	
	C63	Wigle et al., "An Essential Role for <i>Prox1</i> in the Induction of the Lymphatic Endothelial Cell Phenotype," <i>EMBO J.</i> , 21(7):1505-1513 (2002).	
	C64	Xia et al., "siRNA-mediated Gene Silencing <i>in Vitro</i> and <i>in Vivo</i> ," <i>Nat. Biotech.</i> , 20(10):1006-1010 (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/567,630-Conf. #2853
				Filing Date	May 30, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	1655
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	28113/39467A

	C65	International Search Report for International Application No. PCT/EP2004/008819, mailed December 29, 2004.	
	C66	Written Opinion for International Application No. PCT/EP2004/008819, mailed December 29, 2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--